Question 11124 — pharmacy and medications

Summary

Ms. Annaïg Le Meur draws the attention of the Minister of Solidarity and Health to the delay in decisions by the competent administrative authorities regarding new treatments (panobinostat, ixazomib, carfilzomib, daratumumab and elotuzumab) that could improve the daily lives of people suffering from multiple myeloma. Multiple myeloma is a serious disease of the bone marrow caused by the uncontrolled proliferation of certain white blood cells: plasma cells. This proliferation reduces the patients' normal defense antibodies against infections and attacks the bone as well as the bone marrow. The French Association of Multiple Myeloma Patients (AF3M) estimates that 30,000 people are currently affected in France. At the end of 2015, the European Medicines Agency authorized the marketing of these five new drugs in Europe. According to AF3M, the clinical research work undertaken by doctors from the French-speaking Myeloma Intergroup, French and foreign academic institutions as well as certain pharmaceutical laboratories highlight progress for patients, faced with frequent relapses and sometimes fatal outcomes. Unfortunately, the National Medicines Safety Agency (ANSM) was very late in authorizing the marketing of market for these drugs. Also, she asks him to kindly indicate what the Government's intentions are to provide a response, within a reasonable time, concerning the marketing authorization (AMM) of these new drugs.

Machine translation from French. The official text remains authoritative.

Timeline

No timeline events have been ingested for this record yet.

Votes

No vote records are attached yet.

Versions

No version snapshots stored. Document URLs remain at the source.

Documents

No documents linked.

Sponsors

No sponsors or actors listed by the source.

Related records

No cross-record relationships stored yet.